UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For the
month of June, 2009
Commission
File Number: 000-51310
XTL Biopharmaceuticals
Ltd.
(Translation
of registrant's name into English)
Kiryat
Weizmann Science Park
3
Hasapir Street, Building 3, PO Box 370
Rehovot 76100,
Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x Form
40-F ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ¨
Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- N/A
Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated June 12, 2009
is hereby incorporated by reference into the registration statements on Form F-3
(File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL
Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 23,
2007 , October 30, 2007 and August 15, 2008, respectively, and the registration
statements on Form S-8 (File No. 333-148085, File No. 333-148754 and File No.
333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and
Exchange Commission on December 14, 2007, January 18, 2008, and October 28,
2008, respectively.
XTL
Biopharmaceuticals implements share consolidation – No change in ADR
price
XTL
Biopharmaceuticals Ltd. (the "Company") announced today that its Board of
Directors has authorized the implementation of a share consolidation at a
1-for-5 ratio of its outstanding ordinary shares (TASE: XTL, Pink Sheets:
XTLBY.PK). The share capital of the Company will be consolidated so that each
five (5) shares of NIS 0.02 nominal value shall be consolidated into one (1)
share of NIS 0.1 nominal value (the "New Share"). The share consolidation, which
was approved by shareholders at the Company's Shareholder Meeting held on March
18, 2009, will be effective as of June 22, 2009.
The
Company will also change its ADR ratio to so that each ADR shall represent 2 New
Shares of NIS 0.1 par value and therefore there shall be no effective
change in the price of the ADR as quoted on the Pink Sheets.
The
Company believes that in the future should the Company regain its listing on the
Nasdaq Stock Market, the share consolidation will assist in complying with
Nasdaq's regulatory requirements.
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the acquisition, development and
commercialization of therapeutics for the treatment of multiple myeloma and
hepatitis C. XTL will be developing rHuEPO for the treatment of multiple
myeloma. XTL is publicly traded on the Tel-Aviv Stock Exchange (TASE: XTL; Pink
Sheets: XTLBY.PK).
Contact:
David
Grossman, Chief Executive Officer
Tel:
+972-8-930-4411
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
XTL
BIOPHARMACEUTICALS LTD.
|
|
|
|
|
|
|
By:
|
/s/David Grossman
|
|
|
|
David
Grossman
|
|
|
|
Chief
Executive Officer
|
|
|
|
|